Comments
Loading...

Madrigal Pharmaceuticals

MDGLNASDAQ
Logo brought to you by Benzinga Data
$242.25
9.093.90%
At Close: -
$242.25
00.00%
After Hours: 5:02 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$410.00
Lowest Price Target1
$150.00
Consensus Price Target1
$331.13

Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock, Analyst Ratings, Price Targets, Forecasts

Madrigal Pharmaceuticals Inc has a consensus price target of $331.13 based on the ratings of 17 analysts. The high is $410 issued by UBS on March 15, 2024. The low is $150 issued by B of A Securities on April 22, 2024. The 3 most-recent analyst ratings were released by Citigroup, Evercore ISI Group, and JMP Securities on August 8, 2024, August 8, 2024, and July 16, 2024, respectively. With an average price target of $372 between Citigroup, Evercore ISI Group, and JMP Securities, there's an implied 53.56% upside for Madrigal Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
May
1
1
Jun
1
Jul
1
Aug
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Citigroup
Evercore ISI Group
JMP Securities
B. Riley Securities
HC Wainwright & Co.

1calculated from analyst ratings

Analyst Ratings for Madrigal Pharmaceuticals

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Madrigal Pharmaceuticals (MDGL) stock?

A

The latest price target for Madrigal Pharmaceuticals (NASDAQ:MDGL) was reported by Citigroup on August 8, 2024. The analyst firm set a price target for $371.00 expecting MDGL to rise to within 12 months (a possible 53.15% upside). 32 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Madrigal Pharmaceuticals (MDGL)?

A

The latest analyst rating for Madrigal Pharmaceuticals (NASDAQ:MDGL) was provided by Citigroup, and Madrigal Pharmaceuticals maintained their buy rating.

Q

When was the last upgrade for Madrigal Pharmaceuticals (MDGL)?

A

The last upgrade for Madrigal Pharmaceuticals Inc happened on March 15, 2024 when B. Riley Securities raised their price target to $270. B. Riley Securities previously had a sell for Madrigal Pharmaceuticals Inc.

Q

When was the last downgrade for Madrigal Pharmaceuticals (MDGL)?

A

The last downgrade for Madrigal Pharmaceuticals Inc happened on February 27, 2024 when B. Riley Securities changed their price target from $204 to $155 for Madrigal Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Madrigal Pharmaceuticals (MDGL)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Madrigal Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Madrigal Pharmaceuticals was filed on August 8, 2024 so you should expect the next rating to be made available sometime around August 8, 2025.

Q

Is the Analyst Rating Madrigal Pharmaceuticals (MDGL) correct?

A

While ratings are subjective and will change, the latest Madrigal Pharmaceuticals (MDGL) rating was a maintained with a price target of $382.00 to $371.00. The current price Madrigal Pharmaceuticals (MDGL) is trading at is $242.25, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch